Revenue doubled to $287.8m but NPAT collapsed 95.6% on lost HY22 revaluation

EBITDA increased 62.4% to $97.9m, but PBT swung to -$1.5m from $93.3m (-101.6%) and NPAT fell 95.6% to $4.8m from $108.8m. The prior-period NPAT was bolstered by a $132m non-cash investment revaluation gain, which is the main reason the headline year-on-year profit comparison looks far worse than the operating recovery.

Operating cash flow jumped to $140.3m (HY22: $29.6m), but capital investment of $261.6m (HY22: $124.4m) drove FCF pre-lease to -$121.3m. Gross borrowings rose 10.8% to $1.6b, lifting net debt to $1.5b even as net debt/EBITDA fell to 15.8x from 23.5x on stronger earnings.

PBT growth of -101.6% and NPAT growth of -95.6% are dominated by the absence of HY22's $132m revaluation gain rather than a deterioration in the underlying business. EBITDA at +62.4% and revenue at +128.1% are the cleaner read on operating recovery, and both are well above the historical baseline.

Reinvestment intensity is the real cash story. Capex of $261.6m equals 90.9% of half-year revenue and is more than double the prior-period figure. Operating cash flow recovered strongly, but the entire OCF surge and more is being consumed by the capital programme; FCF/NPAT of -2,527.1% and FCF pre-lease of -$121.3m show the recovery is being funded back into the asset base, with gross borrowings up $157.3m to support it.

EBITDA margin sits at an unprecedented low. The 34.0% EBITDA margin is well below the historical mean of 67.6% (range 47.8%–80.7%). The dollar EBITDA has recovered but the cost base has rebuilt faster than revenue per unit of activity, so the margin recovery has further to run before economics return to the pre-disruption shape.

The supplied second-half shape context shows HY22 represented 42.0% of FY22 revenue and 41.7% of FY22 EBITDA, indicating a second-half-weighted pattern; if that shape holds, the implied FY23 revenue run-rate is meaningfully above HY23 annualised at $575.6m.

What the release does not support is any view on margin trajectory: it confirms revenue is returning but not that the EBITDA margin gap to the historical 67.6% mean closes within FY23, and the heavy capex programme means cash returns to shareholders cannot be inferred from operating recovery alone.

However, several quality flags warrant attention.

Cash conversion at 143.3% (OCF/EBITDA) is unprecedented versus Annolyse's historical baseline (4-period mean 53.2%, range 46.3%–67.4%) and should not be extrapolated. Debtor days fell to 18.0, an unprecedented low versus the 29.9-day historical mean, and operating working-capital movement was just $3.1m versus a historical pattern of $20.7m builds in every prior period observed. Both look favourable but timing-related; as activity normalises, working capital should rebuild and conversion should revert toward the historical band.

The 420.0% effective tax rate is mechanically distorted because PBT is near zero (-$1.5m), so a small tax credit produces an outsized rate. PBT growth of -101.6% is the cleaner operating read than NPAT growth.

This briefing cannot assess passenger-volume trajectories, aeronautical pricing settings, or the specific project pipeline behind the capex programme.